Pancreatic Safety of Sitagliptin in the TECOS Study | Zendy

John B. Buse | Zendy; M. Angelyn Bethel | Zendy; Jennifer B. Green | Zendy; Susanna R. Stevens | Zendy; Yuliya Lokhnygina | Zendy; Pablo Aschner | Zendy; Carlos Raffo Grado | Zendy; Tsvetalina Tankova | Zendy; Julio Wainstein | Zendy; Robert Josse | Zendy; John M. Lachin | Zendy; Samuel S. Engel | Zendy; Keyur Patel | Zendy; Eric D. Peterson | Zendy; Rury R. Holman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pancreatic Safety of Sitagliptin in the TECOS Study

Author(s) -

John B. Buse,

M. Angelyn Bethel,

Jennifer B. Green,

Susanna R. Stevens,

Yuliya Lokhnygina,

Pablo Aschner,

Carlos Raffo Grado,

Tsvetalina Tankova,

Julio Wainstein,

Robert Josse,

John M. Lachin,

Samuel S. Engel,

Keyur Patel,

Eric D. Peterson,

Rury R. Holman

Publication year - 2016

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc15-2780

Subject(s) - sitagliptin , medicine , acute pancreatitis , sitagliptin phosphate , pancreatitis , pancreatic cancer , hazard ratio , gastroenterology , placebo , diabetes mellitus , cancer , dipeptidyl peptidase 4 inhibitor , type 2 diabetes , surgery , endocrinology , confidence interval , pathology , alternative medicine

We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research